Are drug targets with genetic support twice as likely to be approved? Revised estimates of the impact of genetic support for drug mechanisms on the probability of drug approval.
King EA, Davis JW, Degner JF. · 2019
Read Are drug targets with genetic support twice as likely to be approved? Revised estimates of the impact of genetic support for drug mechanisms on the probability of drug approval. by King EA, Davis JW, Degner JF. (2019) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6907751.txt.
Description
King and co-authors revisit a famous claim about drug development, in PLOS Genetics. Only about 10 percent of candidate drugs entering early trials win approval. A 2015 study concluded that targets backed by human genetic evidence are twice as likely to succeed. Given the flood of new genome studies since, the figure deserved a fresh test.
Using updated pipeline data, the authors confirm the advantage. Drugs whose targets had genetic support were more likely to pass phase II and phase III trials. The edge was clearest when the causal gene behind the genetic signal could be named with confidence. Their models also adjust for properties of the target and the disease, which sharpen the estimate.
Catalog record
| CREATOR | King EA, Davis JW, Degner JF. |
|---|---|
| YEAR | 2019 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 62 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |